BRAF and melanoma: For disseminated melanoma, immune checkpoint inhibitors have become the mainstay of treatment, although some efficacy has also been shown for the anti proto oncogene B-Raf (BRAF) agents dabrafenib, trametinib, and other drugs in BRAF mutated tumors [2, 3, 16, 19, 20, 22, 28, 30, 44, 47, 49, 51, 60, 73, 79, 80, 83].